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Abstract
There is emerging evidence that amyloid beta (Aβ) aggregates forming neuritic plaques 
lead to impairment of the lipid-rich myelin sheath and glia. In this study, we exam-
ined focal myelin lipid alterations and the disruption of the myelin sheath associated 
with amyloid plaques in a widely used familial Alzheimer's disease (AD) mouse model; 
5xFAD. This AD mouse model has Aβ42 peptide-rich plaque deposition in the brain 
parenchyma. Matrix-assisted laser desorption/ionization imaging mass spectrometry of 
coronal brain tissue sections revealed focal Aβ plaque-associated depletion of multiple 
myelin-associated lipid species including sulfatides, galactosylceramides, and specific 
plasmalogen phopshatidylethanolamines in the hippocampus, cortex, and on the edges 
of corpus callosum. Certain phosphatidylcholines abundant in myelin were also de-
pleted in amyloid plaques on the edges of corpus callosum. Further, lysophosphatidy-
lethanolamines and lysophosphatidylcholines, implicated in neuroinflammation, were 
found to accumulate in amyloid plaques. Double staining of the consecutive sections 
with fluoromyelin and amyloid-specific antibody revealed amyloid plaque-associated 
myelin sheath disruption on the edges of the corpus callosum which is specifically cor-
related with plaque-associated myelin lipid loss only in this region. Further, apolipopro-
tein E, which is implicated in depletion of sulfatides in AD brain, is deposited in all the 
Aβ plaques which suggest apolipoprotein E might mediate sulfatide depletion as a con-
sequence of an immune response to Aβ deposition. This high-spatial resolution matrix-
assisted laser desorption/ionization imaging mass spectrometry study in combination 
with (immuno) fluorescence staining of 5xFAD mouse brain provides new understand-
ing of morphological, molecular and immune signatures of Aβ plaque pathology-associ-
ated myelin lipid loss and myelin degeneration in a brain region-specific manner.
Read the Edito rial Highl ight for this artic le on https://doi.org/10.1111/jnc.15025  
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1  | INTRODUC TION
According to the amyloid hypothesis, accumulation of amyloid beta (Aβ) 
plays a central and causative part in Alzheimer's disease (AD) patho-
genesis and the rest of the disease process (Hardy & Higgins, 1992). Aβ 
aggregates into oligomers that form diffuse and neuritic plaques in the 
brain parenchyma, which have been suggested to cause dysfunction and 
loss of neurons and synapses (Lacor et al., 2004; Palop & Mucke, 2010). 
However, there is also emerging evidence that this process may lead 
to impairment of the lipid-rich myelin sheath and the oligodendrocyte 
degeneration present in the brains of AD patients and transgenic AD 
mice models (Behrendt et al., 2013; Desai, Guercio, Narrow, & Bowers, 
2011; Nasrabady, Rizvi, Goldman, & Brickman, 2018). The presence of 
intracellular granular lipid deposits in multiple cell types and myelin defi-
cits in the brain parenchyma in AD was initially described by Aloysius 
Alzheimer in 1911 (Foley, 2010; Möller & Graeber, 1998). Further, the 
E4 allelic variant of the apolipoprotein (APOE) gene which encodes 
a protein involved in the sterol and sphingolipid metabolism such as 
the modulation of sulfatide content, and lipid transport (Bu, 2009; 
Han, Cheng, Fryer, Fagan, & Holtzman, 2003; Kim, Basak, & Holtzman, 
2009) was suggested to be a prominent risk factor for sporadic AD and 
late-onset familial AD (FAD) (Corder et al., 1993; Saunders et al., 1993; 
Strittmatter et al., 1993). APOE linked the aberrant lipid biochemistry 
to AD pathogenesis in postmortem human AD and transgenic AD mice 
brains (Bandaru et al., 2009; Han, M. Holtzman, W. McKeel, Kelley, & 
Morris, 2002). Therefore, the role of intracellular lipid deposits, lipid 
biochemistry and myelin disruption in association with amyloid pathol-
ogy in AD pathogenesis has been widely scrutinized (Bartzokis, 2004; 
Collins-Praino et al., 2014; Di Paolo & Kim, 2011; Mitew et al., 2010; 
Palavicini et al., 2017; Yang et al., 2014). Morphological data from 
human presenilin-1 familial, sporadic and preclinical AD cases, as well 
as in aged transgenic mice models, tg2576 (APPSwe 670/671) and APP/
PS1 (APPSwe ˟ PS1M146L) has revealed a clear association between the 
fibrillary Aβ pathology and focal disruption of the myelin sheath in the 
gray matter of the neocortex compared with the age-matched control 
tissue (Mitew et al., 2010). Moreover, there was a focal loss of oligo-
dendrocytes in sporadic and preclinical AD cases (Mitew et al., 2010) 
which is in line with the finding that amyloid-β peptides are cytotoxic to 
oligodendrocytes (Xu et al., 2001). However, molecular aspects of these 
observations still remain unknown.
Early lipidomics studies using brain tissue extracts revealed that sul-
fatides and plasmalogens substantially and specifically deplete, while cer-
amides elevate at the very early stages of AD (Han, Holtzman, & McKeel, 
2001a; Han et al., 2002). Further, a body of evidence deduced from 
shotgun lipidomic analysis of brain tissue extracts suggested that APOE 
mediates sulfatide depletion in APP transgenic mice models (Cheng, 
Zhou, Holtzman, & Han, 2010). However, there was no direct correlation 
between sulfatide depletion and amyloid plaque-associated pathol-
ogy. While recent data has revealed focal depletion of several sulfatide 
species in the amyloid plaques in the hippocampus and cerebral cortex 
of the brain in transgenic AD mice models, tgArcSwe (APPE693G(Arctic)/
KM670/671Nl(Swedish)) (Kaya, Brinet, Michno, Başkurt, et al., 2017; Kaya, 
Brinet, Michno, Syvänen, et al., 2017) and tgSwe (APP KM670/671Nl) 
(Michno et al., 2018), it still remains unknown whether these observa-
tions are associated with myelin disruption and/or other factors such as 
APOE in association with amyloid plaques in specific brain regions.
Matrix-assisted laser desorption/ionization imaging mass spectrom-
etry (MALDI-IMS) offers high-throughput spatial interrogation of the 
relative abundances of many lipid species on the surfaces of tissue sec-
tions (McDonnell & Heeren, 2007; Zemski Berry et al., 2011). MALDI-
IMS has been widely used to probe the altered spatial lipid biochemistry 
in brain diseases including AD (Caughlin et al., 2018; Hamilton et al., 
2015; Hong et al., 2016; Kaya, Zetterberg, Blennow, Hanrieder, & r., 
2018b; Yuki et al., 2014), Huntington's disease (Hunter, Demarais, Faull, 
Grey, & Curtis, 2018), mucopolysaccharidosis type II (Hunter's dis-
ease) (Dufresne et al., 2017), traumatic brain injury (Mallah et al., 2018; 
Woods et al., 2013), Tay–Sachs/Sandhoff disease (Chen et al., 2008), 
and Niemann–Pick disease (Tobias, Pathmasiri, & Cologna, 2019) to 
name but a few. Indeed, MALDI-IMS was shown to be a powerful 
approach for probing amyloid plaque-associated lipid biochemistry in 
specific brain regions of transgenic AD mice models (Kaya, Zetterberg, 
et al., 2018). The widely used familial AD mouse model, 5xFAD, contains 
Aβ42 peptide-rich amyloid plaque deposits in brain parenchyma (Oakley, 
Cole, & Logan, 2006). Further, the amyloid plaque-associated lipid bio-
chemistry-related immune proteins have been extensively studied in 
5xFAD mouse brain (Griciuc et al., 2019; Rangaraju et al., 2018; Ulland 
et al., 2017). Hence, lipid molecular information represents an important 
piece of the complex molecular puzzle in amyloid plaques and their in-
terrelated discussion with amyloid plaque pathology might improve the 
understanding of amyloid-associated AD pathogenesis.
In this study, high-spatial resolution MALDI-IMS of coronal brain 
tissue sections of 12-month-old 5xFAD mice revealed focal amyloid 
plaque-associated depletion of several myelin-associated lipid spe-
cies. Double staining of the consecutive sections with fluoromyelin 
and amyloid-specific antibodies revealed amyloid plaque-associated 
myelin lipid disruption which was specific to the edges of the corpus 
callosum in the white matter while there was no disruption of the 
myelin sheath observed in amyloid plaque-rich areas in several other 
brain regions in the gray matter. APOE accumulation in amyloid 
plaques was found to be in line with sulfatide depletion in several 
brain regions, suggesting that sulfatide depletion might be APOE 
deposition-associated in all the plaques in the white and gray matter 
regions in 5xFAD mouse brain. Our data suggests amyloid plaque pa-
thology-associated disruption of the myelin sheath through the loss 
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of myelin lipids which leverages the understanding of gray matter 
and white matter pathologies in AD.
2  | MATERIAL S AND METHODS
2.1 | Chemicals and reagents
All chemicals for matrix and solvent preparation were pro-analysis 
grade and obtained from Sigma-Aldrich (Stockholm) unless otherwise 
specified. Anti-beta amyloid antibody (rabbit polyclonal to beta amy-
loid), anti-APOE antibodies (rabbit monoclonal to apolipoprotein E) 
and thioflavin S, DAPI fluorescent stains were purchased from Abcam. 
FluoroMyelin™ green fluorescent myelin stain was purchased from 
ThermoFisher Scientific (Stockholm). TissueTek optimal cutting tem-
perature (OCT) compound was purchased from Sakura Finetek (AJ 
Alphen aan den Rijn). The deionized H2O was obtained from a Milli-Q 
purification system (Merck Millipore).
2.2 | Animals, tissue sampling and sectioning
The 5xFAD transgenic mouse model was purchased from Jackson 
Laboratory (Bar Harbor). These transgenic AD mice co-express five FAD 
mutations [APP K670N/M671L (Swedish) + I716V (Florida) + V717I 
(London) and PS1 M146L + L286V]. All mutations are specific to 
FAD and their expression is regulated under the control of the Thy-1 
promoter to drive overexpression only in the brain. This exploratory 
animal study was not pre-registered. No randomization, blinding, and 
sample calculation was performed. No exclusion criteria were prede-
termined and no animals were excluded. All mice were obtained by 
breeding the 5xFAD mouse (Tg6799; The Jackson Laboratory) with 
B6SJLF1/J (The Jackson Laboratory). The animals were housed in in-
dividually ventilated cages and each cage housed 4–6 mice. All mice 
were kept at 20°C and 12-hr day/12-hr night cycle. Food and water 
were available ad libitum. Serial sections from the male 12-month-old 
transgenic (5xFAD) mice were used as the experimental group (n = 4) 
(mean weight: 23.4 g) and male non-transgenic littermates (LM) were 
used as the control animals (n = 4) (mean weight: 30.1 g). All animal 
procedures were approved by the Ethics Committee of the Animal 
Care and Use Committee of Acibadem Mehmet Ali Aydinlar University, 
Istanbul, Turkey (Approval ID: HDK-2016/13). The animals were an-
esthetized to minimize suffering with isoflurane and sacrificed by de-
capitation. The brains were dissected within 3 min postmortem delay 
and frozen on dry ice. Frozen tissue sections (10 μm thick) were cut 
in a cryostat microtome (Leica CM 1520; Leica Biosystems) at −20°C, 
and collected on indium tin oxide (ITO)-coated glass slides (Bruker 
Daltonics) and stored at −80°C. The control and transgenic mice brains 
were cut on the same ITO glasses (three sections for each) to avoid 
the effect of sample preparation variance during MALDI-IMS analysis. 
Immunohistochemistry and fluorescence staining experiments were 
performed on the direct consecutive tissue sections unless otherwise 
specified.
2.3 | Sample preparation and matrix application for 
MALDI-IMS
For MALDI-IMS in dual polarity, 1,5-diaminonapthalene matrix 
was deposited onto the tissue by sublimation-based matrix coating 
(Thomas, Charbonneau, Fournaise, & Chaurand, 2012). Matrix depo-
sition for lipid analysis was carried out using a vacuum sublimation 
apparatus (Sigma-Aldrich) as previously described in detail elsewhere 
(Kaya, Jennische, Lange, & Malmberg, 2018a). 1,5-Diaminonapthalene 
matrix was deposited over the brain tissue sections with the optimized 
sublimation parameters: 20 min at a temperature of 130°C under a 
stable vacuum of ~0.8 mbar according to the previously published re-
ports (Kaya, Michno, et al., 2017).
2.4 | MALDI-MS and MALDI-IMS and MALDI-MS/
MS analyses
IMS analysis of tissue sections was performed on a MALDI-TOF/TOF 
UltrafleXtreme mass spectrometer equipped with a SmartBeam II 
Nd:YAG/355 nm laser operating at 1 kHz (Bruker Daltonics). MALDI-
IMS data for lipids over a mass range of 300–3000 Da. was collected 
in reflective ion mode using 5–10 laser shots per pixel in negative 
polarity and 20–25 laser shots in positive polarity as previously de-
scribed in detail elsewhere (Kaya, Michno, et al., 2017). External cali-
bration was carried out using Peptide Calibration Standard I (Bruker 
Daltonics) solution (4 pmol/μl) spotted next to the tissue sections 
prior to sample preparation. Image data were reconstructed and visu-
alized using Flex Imaging v3.0 (Bruker Daltonics). For Aβ peptide anal-
yses on the brain tissue sections, spectral profiling data acquisitions 
were performed in linear positive ion mode by collecting 100 laser 
shot-spectra over a mass range of 2,000–10,000 Da. Identification of 
lipids and amyloid peptides (Aβ 1–40, Aβ 1–42) was performed by ex-
amining MS/MS spectra obtained in laser induced dissociation (LID)-
TOF/TOF mode and comparing the diagnostic fragment ions from the 
LIPID MAPS database (Nature Lipidomics Gateway, www.lipid maps.
org) and previously published studies (Zemski Berry et al., 2011). LID-
MALDI-TOF/TOF MS/MS spectra obtained from the precursor ions of 
lysophosphatidylcholine (LPC 16:0) (m/z 496.3), Cer(36:1 (m/z 564.6), 
and PE(36:1p) (m/z 728.5) along with the fragmentation pathways 
proposed for each molecule are provided as examples (Figure S1).
The localization of Aβ 1–40 and Aβ 1–42 in 5xFAD mouse brain 
has previously been shown on these samples (Kaya et al., 2019), with 
MALDI-MS and MALDI-IMS which are able to distinguish between the 
Aβ 1–40 and Aβ 1–42 in AD brain tissues (Carlred et al., 2016; Stoeckli, 
Staab, Staufenbiel, Wiederhold, & Signor, 2002). Here we focus solely 
on the lipid changes associated with the plaques and instead correlate 
the MALDI-IMS with immunohistochemical staining of the plaques.
Quantitative analysis of MALDI-MSI data is notoriously difficult. 
So as not to imply quantitation with the inclusion of numerical sta-
tistics the robustness and reproducibility of the results are demon-
strated by the inclusion of multiple images from multiple 5xFAD and 
littermate control mice (Figures S6, S7).
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2.5 | Immunohistochemistry, fluorescence 
staining, and hematoxylin staining
In order to visualize amyloid aggregates, the tissue sections were 
fixed in methanol, blocked with 2.5% horse serum and incubated with 
a rabbit polyclonal antibody against β-amyloid (ab2539; Abcam) di-
luted 1:2000 in phosphate-buffered saline (PBS), overnight. Impress 
reagent, anti-rabbit Ig (Vector Laboratories) was used as secondary 
reagent and the reaction was visualized using Liquid DAB + sub-
strate chromogen system (DAKO). Nuclei were counterstained 
with hematoxylin and the sections were dehydrated and mounted 
in DPX (Merck). The sections were scanned using a slide scanner 
(NanoZoomer SQ; Hamamatsu Photonics). For myelin and amyloid 
double staining, the sections were fixed in 4% buffered formal-
dehyde for 5 min, rinsed in PBS and incubated with a rabbit poly-
clonal antibody against β-amyloid (ab2539; Abcam) diluted 1:1,000 
in PBS, overnight. A Cy3 conjugated donkey anti-rabbit IgG diluted 
1:300 in PBS, was used as the secondary reagent (Jackson labora-
tories 711-166-152). After rinsing, the sections were incubated for 
20 min with FluoroMyelin™ green fluorescent myelin stain (F34651; 
Molecular Probes) diluted 1:300 in PBS. Nuclei were stained with bis-
benzimide (33342; Hoechst) trihydrochloride (14533; Sigma Aldrich) 
diluted to 2.5 µg/ml in distilled water. The sections were mounted in 
Vectashield (Vector laboratories) and viewed with a Zeiss Axio Imager 
M1 microscope using the appropriate filter combinations. For APOE 
and amyloid double staining, the sections were fixed in methanol, 
air dried, and incubated with a rabbit monoclonal antibody against 
Apolipoprotein E (ab19378; Abcam) diluted 1:1,000 in PBS, overnight. 
Cy3 conjugated donkey anti-rabbit IgG was used as the secondary re-
agent (711-166-152; Jackson Laboratories) diluted 1:300 in PBS. After 
rinsing the sections were incubated with Thioflavin S (T1892; Sigma) 
2mg/ml in PBS for 20 min. The sections were mounted in Vectashield 
(Vector Laboratories) and viewed with a Zeiss Axio Imager M1 micro-
scope using the appropriate filter combinations. For general histology, 
the sections were fixed in methanol, immersed in Harris hematoxylin 
(Histolab Products AB) for 45 s, rinsed in water and immersed in 0.2% 
eosin in ethanol (Histolab Products AB) for 30 s. The sections were 
then dehydrated and mounted in DPX (Merck).
3  | RESULTS
3.1 | Myelin lipids are depleted in amyloid plaques 
in the hippocampus, cortex and on the edges of 
corpus callosum
Initially, chromogenic staining of amyloid plaques with anti-beta amy-
loid antibody and hematoxylin staining was performed on a coronal 
tissue section to reveal the plaque distributions over the brain regions 
in 12-month-old 5xFAD mice brains. Amyloid plaques were visualized 
abundantly in the cornu ammonis (CA), subiculum and deep cortical 
layers (Figure S2). For the inspection of the amyloid plaque-associated 
alterations of myelin lipids, regions containing both white matter and 
gray matter areas including the cortex, corpus callosum, and CA re-
gion in the hippocampus in coronal sections of 12-month-old 5xFAD 
mice brains were imaged using MALDI-IMS at 10 μm spatial resolution 
in negative and positive polarities (Figures 1 and 2). Further, consecu-
tive tissue sections were stained with an anti-Aβ antibody and hema-
toxylin to distinguish amyloid plaques and brain regions, respectively 
(Figures 1a and 2a,m). Inspection of the ion images (in green) obtained 
in negative polarity analysis revealed significant focal depletion of 
both hydroxylated and non-hydroxylated sulfatides (ST), irrespective 
of their fatty acid (FA) moiety (Figure 1b–g), along with galactosylcera-
mides (GalCer) (Figure 1h–j) and some plasmalogen phosphatidyletha-
nolamines (PEp) (Figure 1k,l) in the hippocampal and cortical amyloid 
plaques in a coronal tissue sections of 12-month-old 5xFAD mice brain 
(Figure 1a). Inspection of the ion images (in green) obtained in positive 
polarity analysis revealed relatively less clear depletion of phosphati-
dylcholines (PC) (abundant in the myelin-rich corpus callosum) on the 
edges of the corpus callosum, whereas no clear depletion of these spe-
cies was observed in the amyloid plaques in the cortex and CA regions 
in the gray matter (Figure 2b–d). PC species that were most abundant 
in the gray matter revealed no clear depletion in amyloid plaques in 
the gray or white matter (Figure 2e,f). Furthermore, LPCs (Figure 2g,h) 
and lysophosphatidylethanolamines (LPEs) (Figure 2p,q) were found to 
be accumulated in amyloid plaque areas in line with the depletion of 
certain PCs (Figure 2i–l) and PEps (Figure 2r). MALDI-IMS analysis of a 
different brain region containing the subiculum, CA and adjacent corti-
cal areas revealed that ceramides, which are the possible precursor/
degradation products of sulfatides, were found to be accumulated in 
amyloid plaques, particularly in the subiculum and adjacent CA region 
in line with the severe depletion of sulfatides (Figure 3). Chromogenic 
amyloid-specific immunostaining did not reveal any plaque-like accu-
mulations in the brains of age-matched littermate control mice brain. 
Further, MALDI-IMS revealed distributions of the lipid species in the 
age-matched littermate control mice brain and there were no plaque-
like accumulations/depletions of the same lipid species in the equivalent 
brain regions where plaque-associated lipid changes were observed in 
12-month-old 5xFAD mice brain (Figure S3, S4). In addition, to increase 
the confidence in observations, MALDI-IMS of lipids and immunofluo-
rescence amyloid staining of the same coronal tissue section of 5xFAD 
mice brain was performed which demonstrated localization of amyloid 
plaques and associated lipid alterations (Figure S5).
Ion images (obtained with MALDI-IMS in positive and negative 
polarities at 10 μm per pixel spatial resolution) of STs, GalCers, 
PEps, PCs, LPEs and LPCs from the coronal brain tissue sections of 
three 12-month-old 5xFAD mice are provided in Figure S6 and S7.
3.2 | Myelin structure is disrupted in the edges of 
corpus callosum in the white matter
While ion images of the aforementioned STs, GalCers, Peps, and cer-
tain PCs indicate their clear abundance in the myelin-rich corpus cal-
losum (Figure 1) in the white matter and their depletion in amyloid 
plaques, it is not certain if the amyloid plaque-associated myelin lipid 
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loss is correlated with structural disruption of the lipid-reach myelin 
sheath in 5xFAD mouse brain. Since myelin is a particularly lipid-reach 
brain region; one would expect plaque-associated structural deforma-
tion of the myelin sheath due to the lipid loss. Therefore, consecutive 
coronal tissue sections were double stained with fluoromyelin fluo-
rescence and anti-amyloid immunofluorescence (Figure 4a–c). This 
revealed clear amyloid plaque-associated myelin disruption but only 
on the edges of the corpus callosum in the white matter (Figure 4d–f). 
The myelin structure was not disrupted in amyloid plaque areas in 
several other brain regions including the cortex (Figure 5a–c), den-
tate gyrus (Figure 5d–f), CA (Figure 5g–I), and subiculum (Figure 5j–l) 
in the gray matter. This suggests amyloid plaque-associated disrup-
tion of the lipid reach myelin sheath which links amyloid pathology to 
white matter lipid degeneration. Results from three more 12-month-
old 5xFAD mice brains are presented in Figure S8.
3.3 | APOE is present in amyloid plaques in the gray 
matter and on the edges of corpus callosum
APOE is synthesized and secreted primarily by astrocytes and micro-
glia in the CNS (Boyles, Pitas, Wilson, Mahley, & Taylor, 1985; Nakai, 
Kawamata, Taniguchi, Maeda, & Tanaka, 1996). As mentioned above, 
it has been postulated that APOE mediates sulfatide depletion in APP 
transgenic mice models using shot gun lipidomic analysis of brain tis-
sue extracts (Cheng et al., 2010). It has also been reported that the 
densities of astrocytes (glial fibrillary acidic protein) and microglia 
(F4/80) implicated in neuroinflammation are increased in/around 
Aβ42-rich amyloid plaques in aged 5xFAD mouse brain (Oakley et al., 
2006) which suggests a possible route for accumulation of APOE in/
around amyloid plaques. Therefore, to test if APOE is accumulated and 
can be correlated with severe sulfatide depletion in amyloid plaques in 
F I G U R E  1   Matrix-assisted laser desorption/ionization imaging mass spectrometry (MALDI-IMS) reveals focal depletion of myelin lipids 
in amyloid plaques in the hippocampus, cortex and on the edges of corpus callosum in coronal brain tissue sections of 12-month old 5xFAD 
mouse (n = 4 mice, n = 3 sections each). (a) The spatial distribution of amyloid aggregates (brown aggregates) in the hippocampus and 
adjacent cortical regions was visualized with anti-beta amyloid antibody and counter staining with hematoxylin (CC: corpus callosum, CTX: 
cortex, pl: pyramidal layer). Significant depletion of several hydroxylated and non-hydroxylated sulfatides; (b) ST(40:0-2OH) (m/z 878.6), (c) 
ST(42:2) (m/z 888.6), (d) ST(42:1) (m/z 890.6), (e) ST(42:0) (m/z 892.6), (f) ST(42:2-2OH) (m/z 904.6), (g) ST(42:2-2OH) (m/z 906.6), irrespective 
of their fatty acid moiety, along with the depletion of some galactosylceramides; (h) (GalCer) (42:0) (m/z 812.3), (i) GalCer(42:1) (m/z 810.3), 
(j) GalCer(42:1-2OH) (m/z 848.3) and plasmalogen phosphatidylethanolamines; (k) PE(36:2p) (m/z 726.5), (l) PE(36:1p) (m/z 728.5) in amyloid 
plaques in the hippocampus, cortex and on the edges of corpus callosum. Ion images of putatively assigned lysophosphatidylethanolamine 
(LPE) (13:0) (m/z 410.3) in blue were overlayed to highlight pyramidal cell layers in panels (b–l) for clearer visualization of the data and 
comparison with the stained image in (a). MALDI-IMS analysis was performed at 10 μm per pixel spatial resolution in negative ion mode. Ions 
are either [M + H]+ or [M−H]− unless otherwise specified otherwise. Scale bar in panel (A) is 200 μm
(a) (b) (c) (d) (e) (f)
(g) (h) (i) (j) (k) (l)
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F I G U R E  2   Matrix-assisted laser desorption/ionization imaging mass spectrometry (MALDI-IMS) reveals focal depletion of certain 
phosphatidylcholines (PCs) that are abundant in myelin-rich corpus callosum are depleted in amyloid plaques on the edges of the corpus 
callosum (see yellow arrows in panel (b–d) for the depletion areas) (n = 4 mice, n = 3 sections each). Lysophosphatidycholines (LPCs) are 
accumulated in amyloid plaques in the whiter matter and grey matter. Accumulations of lysophosphatidylethanolamines were observed 
in the amyloid plaques where plasmalogen phosphatidylethanolamines are depleted. (a, m) Spatial distribution of amyloid aggregates 
(brown aggregates) in the hippocampus and adjacent cortical regions was visualized with anti-beta amyloid antibody and counter staining 
with hematoxylin. Ion images of phosphatidylcholines (b) PC(36:1) (m/z 788.6), (c) PC(36:1)+K (m/z 826.6), (d) PC(38:4)+K (m/z 848.6), (e) 
PC(34:1) (m/z 760.6), (f) PC(34:1)+K (m/z 798.6), (g) LPC(16:0) (m/z 496.3), (h) LPC(18:0) (m/z 524.3), (i) merged PC(36:1) (m/z 788.6) (green), 
LPC(16:0) (m/z 496.3) (red), (j) merged) PC(36:1)+K (m/z 826.6) (green), LPC(16:0) (m/z 496.3) (red), (k) PC(38:4)+K (m/z 848.6) (green) 
and LPC(16:0) (m/z 496.3) (red), (l) PC(38:4)+K (m/z 848.6) (green) and LPC(18:0) (m/z 524.3) (red), (n) PE(36:2p) (m/z 726.5). Imaging of 
phosphatidylethanolamines (o) PE(36:1p) (728.5), (p) lysophosphatidylethanolamine (LPE) (16:0) (m/z 452.5), (q) LPE(18:0) (m/z 480.5), (r) 
merged PE(36:1p) (728.5) (green) and LPE(18:0) (m/z 480.5) (red). Ion images of putatively assigned LPE(13:0) (m/z 410.3) in blue were 
overlayed to highlight pyramidal cell layers in panels (n–r) for better visualization of the data. MALDI-IMS analysis was performed at 10 μm 
per pixel spatial resolution in positive (b–l) and negative (n–r) ion modes. Ions are either [M + H]+ or [M−H]− unless otherwise specified 
otherwise.CC, corpus callosum; CTX, cortex; CA, cornu ammonis; pl, pyramidal layer; gcl, granular cell layer. Scale bars, panels (a, m), 200 μm
(a) (b) (c) (d) (e) (f)
(g) (h) (i) (j) (k) (l)
(m) (n) (o) (p) (q) (r)
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the gray matter and on the edges of the corpus callosum in 12-month-
old 5xFAD mouse brain (Figure 1), coronal brain tissue sections were 
double stained with thioflavin S and monoclonal anti-APOE antibody 
(Figure 6). The results showed accumulation of APOE protein in all the 
amyloid plaques in the gray matter and on the edge of the corpus cal-
losum supporting the hypothesis of an association of APOE with sulfa-
tide depletion in the amyloid plaques in 12-month-old 5xFAD mouse 
brain. Results from three other 12-month-old 5xFAD mice brains are 
presented in Figure S9.
4  | DISCUSSION
The myelin sheath is a lipid rich, multilamellar extension of the 
plasma membrane of oligodendrocytes. In contrast to most biologi-
cal membranes, myelin contains remarkably high lipid levels which 
account for 70%–85% of its dry weight (Wang, Palavicini, & Han, 
2018). Lipidomics studies have revealed that galactosylceramide and 
their sulfated form, sulfatides, are the most typical lipids of myelin, 
where they are highly enriched and their abundance was found to be 
proportional to the amount of myelin present in the rat brain (Norton 
& Poduslo, 1973). In addition to galactolipids, cholesterol, ethanol-
amine-containing plasmalogens, phosphatidylethanolamines, phos-
phatidycholines and sphingomyelin are also major lipid constituents 
of the myelin sheath (Norton & Poduslo, 1973) (Wang et al., 2018).
This study reports the loss of myelin-associated lipids, disrup-
tion of myelin sheath, and APOE deposition localized to amyloid 
plaques in aged (12-month-old) 5xFAD mouse brain tissue. The 
goal was to shed further light on the molecular, morphological, and 
immune signatures of myelin lipid loss in association with amyloid 
pathology in AD in a spatially specific manner. Amyloid plaques are 
exceedingly rare in the white matter in AD pathology (Nasrabady 
et al., 2018). This is apparent here with 12 month-old 5xFAD mouse 
brain in which we observed amyloid plaque accumulations abun-
dantly in the gray matter areas including subiculum, cortex, CA and 
DG, while there were a few plaques visible on the edges of corpus 
callosum in the white matter (Figure S2b). The presence of the lat-
ter results in a direct exposure of myelin-rich corpus callosum in 
the white matter to amyloid plaques rich in Aβ 1–42 and Aβ 1–40 
(Oakley et al., 2006).
It was previously demonstrated that Aβ peptides, particularly Aβ 
1–42, are toxic to oligodendrocytes and can lead to their increased 
apoptotic cell death (Desai et al., 2010; Xu et al., 2001). The abundant 
lipid structural components of the myelin sheath, sulfatides, are mainly 
found in oligodendrocytes (the myelinating cells) in the CNS (Hirahara 
et al., 2017), whereas low amounts have been detected in neurons and 
astrocytes (Isaac et al., 2006). Therefore, it can be inferred that Aβ-
induced degeneration of oligodendrocytes might lead to severe loss 
of myelin lipids, particularly sulfatides, which can cause degeneration 
of the myelin sheath in amyloid plaques on the edges of the corpus 
callosum as observed here. Shotgun lipidomic analysis of brain tissue 
extracts has previously revealed that decreases in sulfatide levels co-
incide with the elevation of ceramides in early stages of AD (Han et al., 
2002). Here, MALDI-IMS reveals co-localization of the accumulation of 
ceramides and the depletion of sulfatides in amyloid plaques in several 
brain regions including cortex, subiculum and CA and on the edges of 
corpus callosum in the 5xFAD mouse brain (Figure 3). While ceramides 
may arise as possible precursor/degradation products of sulfatides, a 
body of evidence suggests that the ceramide elevation results from 
Aβ-mediated activation of sphingomyelinases (SMases) that catalyze 
the breakdown of sphingomyelins (SMs) to ceramides (Jana & Pahan, 
2004; Lee et al., 2004). Grimm et al. reported increased activity of 
SMases in presenilin-FAD mutations (that also exist in 5xFAD), where 
Aβ1-42 directly activates neutral SMase (Grimm et al., 2005). In our 
imaging analysis, no clear changes in sphingomyelin levels in amyloid 
plaques were observed in 12 month old 5xFAD mouse brain (data not 
shown).
The mechanism of sulfatide depletion in amyloid plaques still 
remains elusive. The content of sulfatides in the CNS is modulated 
by APOE protein in an isoform-dependent manner through APOE-
containing CNS lipoproteins (Han et al., 2003). APOE, the lipid 
transport protein expressed by microglia (Nakai et al., 1996) and as-
trocytes (Boyles et al., 1985) in the brain was also evidenced to be 
essential for Aβ deposition in APPV717F AD mouse model (Bales et al., 
1999). To identify the mechanisms of sulfatide depletion in AD, Han 
et al. (Han, 2007) proposed a working mechanism which suggests 
APOE-associated lipoprotein particles released from astrocytes can 
acquire sulfatides from the myelin sheath through a ‘’kiss-and-run’’ 
mechanism. This is then followed by metabolism and degradation 
of the resulting sulfatide-containing APOE-associated lipoprotein 
particles through endocytic pathways. This hypothesis was tested 
by Cheng et al. (Cheng et al., 2010) using two human APP express-
ing tg mice, PD (APPV71F) and tg2576 (APPSwe 670/671), both of which 
display extensive amyloid plaques. Analysis by shotgun lipidomics 
was used to demonstrate that the sulfatide levels were reduced in 
both animals in an Aβ pathology-dependent and age-dependent 
manner and sulfatide depletion did not occur in APP mutant, APOE 
null (APOE−/−) animals relative to the APOE−/− controls. This provides 
evidence for the association of APOE with sulfatide depletion in AD 
pathogenesis (Cheng et al., 2010). Further, the brains of APP tg mice, 
tg2576 (APPSwe 670/671), and indeed 5xFAD (Hong et al., 2013) have 
higher APOE levels relative to age-matched controls. Accumulation 
of astrocytes (glial fibrillary acidic protein) and microglia (F4/80) as a 
response to amyloid pathology in 5xFAD mouse brain (Oakley et al., 
2006) suggests a possible route for accumulation of APOE in/around 
amyloid plaques. In our study, we imaged the APOE distribution and 
observed clear deposition of APOE in/around the amyloid plaques 
in the gray and white matter in 12-month-old 5xFAD mouse brain 
(Figure 6). This is in line with the severe depletion of several sulfatide 
species in all the amyloid plaques in the grey matter and white mat-
ter (Figure 1). Thus, it can be hypothesized that the elevated levels 
of APOE, a result of the immune response to amyloid deposition, 
irrespective of the brain region, can facilitate the depletion of sul-
fatides through APOE-associated lipoprotein metabolism in/around 
Aβ plaques.
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Significant depletion of ethanolamine plasmalogen phospho-
lipids has been reported in human AD subjects and transgenic AD 
mice models (Ginsberg, Rafique, Xuereb, Rapoport, & Gershfeld, 
1995; Han et al., 2001b; Igarashi et al., 2011) and this depletion is 
AD specific compared to the primary site of neurodegeneration 
in either Huntington's disease (caudate nucleus) or Parkinson's 
disease (substantia nigra) (Ginsberg et al., 1995). PC species were 
also reported to be diminished in AD subjects (Whiley et al., 2014). 
Oxidative stress (Farooqui, Rapoport, & Horrocks, 1997), inflamma-
tion (Katafuchi et al., 2012), and peroxisome dysfunction (Kou et al., 
2011) are possible amyloid plaque-associated mechanisms that have 
been proposed for plasmalogen depletion in AD. Indeed, Aβ pep-
tide deposits, damaged neurons, and glial cells are obvious stimuli 
for focal inflammation in AD due to their discrete, localized accu-
mulation (Akiyama et al., 2000; Heneka et al., 2015). Amyloid pep-
tides and inflammatory mediators accumulated in amyloid plaques 
can upregulate the activity of PLA2 enzymes which can result in the 
depletion of plasmalogen PEs and phosphatidylcholines in amyloid 
plaques. Indeed, partial accumulation of PLA2 around Aβ plaques 
has been shown by immunostaining in 5xFAD mouse brain, which 
suggests a stimulated activity of this enzyme and underlies focal am-
yloid-associated inflammatory processes (Hong et al., 2016). Here, 
accumulations of LPE and LPC species in amyloid plaques (Figure 3) 
suggest a mechanism involving inflammatory activation of PLA2 in 
association with amyloid plaques. On the other hand, plaque-asso-
ciated oxidative stress can result in degradation of plasmalogens by 
reactive oxygen species (ROS). Plasmalogens are particularly suscep-
tible to oxidative stress due to a vinyl-ether group in their molecular 
structure and may act as scavengers to protect lipids and lipopro-
teins from oxidative damage (Su, Wang, & Sinclair, 2019). Therefore, 
depletion of plasmalogens can exacerbate the focal oxidative dam-
age to the lipids and proteins in amyloid plaques in 5xFAD mice 
brains. Additionally, increased levels of Aβ-induced ROS can also in-
duce peroxisomal dysfunction, thus reducing alkyl-dihdroxyacetone 
phosphate synthase (AGPS) protein stability, which in turn decreases 
PE-PL synthesis, due to the dysfunction in peroxisomes where plas-
malogens are biosynthesized (Grimm et al., 2011).
Upregulation of LPC species in amyloid plaques can be also impli-
cated in focal demyelination (Mitew et al., 2010). LPC induces focal 
demyelination (Allt, Ghabriel, & Sikri, 1988; Hall, 1972) and disrupts 
myelin lipids nonspecifically (Plemel et al., 2018). This is in line with 
the myelin lipid loss in amyloid plaques, particularly in the myelin lip-
id-rich corpus callosum, in aged 5xFAD mouse brain (Figure 3), which 
might suggest a role of LPC for the disruption of the lipid-rich myelin 
sheath in this region.
Additionally, depletion of myelin lipids in amyloid plaques can 
be involved in the discussion of well-studied lipid metabolism-re-
lated amyloid plaque immunity in 5xFAD mouse brain such as the 
studies on the microglial receptor, triggering receptor expressed on 
myeloid cells 2 (TREM2). TREM2 lipid sensing was shown to sus-
tain microglial response and metabolic fitness around the amyloid 
plaques and limits the diffusion and toxicity of amyloid plaques 
(Wang et al., 2016) in 5xFAD mice brain. Human TREM2 reporter 
cells were found to be stimulated by various phospholipids and 
non-phosphate anionic and zwitterionic lipids including sulfatides 
(Ulland et al., 2017; Wang et al., 2015). Further, elevated TREM2 
expression in microglia by elevated TREM2 gene dosage in 5xFAD 
mice reshapes microglial response which ameliorates AD neuro-
pathology (Lee et al., 2018). Therefore, it might be hypothesized 
that significant focal loss of anionic sulfatides and plasmalogen PEs 
might impair TREM2 lipid sensing, particularly in the myelin lip-
id-rich corpus callosum, and limit the microglial activation for deg-
radation of Aβ in 5xFAD mice brain.
Taken together, high-spatial resolution MALDI-IMS of coronal brain 
tissue sections of 12-month-old 5xFAD mouse revealed focal amyloid 
plaque-associated depletion of several myelin-associated lipid species. 
Double staining of the consecutive sections with fluoromyelin and am-
yloid-specific antibody revealed amyloid plaque-associated myelin lipid 
disruption which occurs specifically on the edges of the corpus callo-
sum in the white matter while there was no disruption of myelin sheath 
observed in amyloid plaque areas in several other brain regions in the 
grey matter. APOE accumulation in amyloid plaques is in line with sul-
fatide depletion in several brain regions suggesting that sulfatide deple-
tion might be APOE deposition associated as an immune response to 
amyloid aggregation in all the plaques in the white and grey matters in 
5xFAD mouse brain. Our data leverage the understanding of morpho-
logical, molecular, and immune signatures of amyloid plaque-associ-
ated myelin lipid loss in a brain region-specific manner. It is particularly 
F I G U R E  3   Matrix-assisted laser desorption/ionization imaging mass spectrometry (MALDI-IMS) reveals colocalized depletions of 
sulfatides and elevations of long-chain ceramides in amyloid plaques in the cortex, and hippocampus in 12-month old 5xFAD mouse brain 
(n = 4 mice, n = 3 sections each). (a) Spatial distribution of amyloid aggregates (brown aggregates) in the hippocampus and adjacent cortical 
regions in 12-month-old 5xFAD mouse brain visualized with anti-beta amyloid antibody and counterstaining with hematoxylin. Ion images 
of sulfatides, (b) ST(36:1) (m/z 806.6), (c) ST(40:1) (m/z 862.6), (d) ST(40:2-2OH) (m/z 878.6), (e) ST(42:2) (m/z 888.6), (f) ST(42:1) (m/z 890.6), 
(g) ST(42:2-2OH) (m/z 904.6), (h) ST(42:1-2OH) (m/z 906.6) reveals their clear depletion in amyloid plaques while ion images of ceramides, 
(i) (Cer(36:1) (m/z 564.6), (j) CerP (42:1) (m/z 648.6) show accumulation in amyloid plaques. Exemplified merged ion images of sulfatides and 
ceramides, (k) ST(36:1) (m/z 806.6) and (Cer(36:1) (m/z 564.6), (l) ST(42:2) (m/z 888.6) and (Cer(36:1) (m/z 564.6), (m) ST(42:1) (m/z 890.6) and 
(Cer(36:1) (m/z 564.6), (n) ST(42:2) (m/z 888.6) and CerP (42:1) (m/z 648.6), (o) ST(42:1) (m/z 890.6) and CerP (42:1) (m/z 648.6) reveals the 
clear colocalization of the depletion of sulfatides and accumulation of ceramides in amyloid plaques in 12-month-old 5xFAD mouse brain. Ion 
images of putatively assigned lysophosphatidylethanolamine (LPE) (13:0) (m/z 410.3) in blue were overlayed to highlight pyramidal cell layers 
in panels (b–o) for better visualization of the data. MALDI-IMS analysis was performed at 10 μm per pixel spatial resolution in negative ion 
mode. Ions are either [M + H]+ or [M−H]− unless otherwise specified otherwise. CC, corpus callosum; CTX, cortex; CA, cornu ammonis; SUB, 
subiculum; pl, pyramidal layer; gcl, granular cell layer. Scale bars, panels (a, m), 200 μm
     |  9KAYA et Al.
(a) (b) (c) (d) (e)
(f) (g) (h) (i) (j)
(k) (l) (m) (n) (o)
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F I G U R E  4   Double staining of coronal brain tissue sections with FluoroMyelin (in green), and anti-amyloid beta (Aβ) antibody (in red) 
reveals focal amyloid plaque-associated disruption of myelin on the edge of corpus callosum in the white matter of 12-month-old 5xFAD 
mice brain (n = 4 mice, n = 3 sections each). Coronal tissue sections were stained with (a) FluoroMyelin (in green) and (b) anti-Aβ antibody 
(in red). Panel (c) shows the merged images of FluoroMyelin (in green), anti-Aβ antibody (in red) and Hoechst staining (in blue). Panels (d–f) 
contain the zoomed images from the dashed squares in panels (a–c) showing the disruption of the myelin sheath (d), the amyloid plaque (e) 
and an overlay of these images (f) in the corpus callosum. Further examples of the disrupted myelin sheath in the amyloid plaques on the 
edges of corpus callosum are shown in panels (g–i), (j–l), (m–o), and (p–r). Hipp, Hippocampus; CA, cornu ammonis; CC, corpus callosum; CTX, 
cortex; TH, Thalamus; DG, dentate gyrus; Hipp, hippocampus; pl, pyramidal layer; gcl, granule cell layer. Original magnification, panel (a–c) 
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FIGURE 5 Double staining of coronal brain tissue sections with (a, d, g, j) FluoroMyelin (in green), and (b, e, h, k) anti-amyloid beta (Aβ) antibody 
(in red) shows no evidence of focal amyloid plaque-associated disruption of myelin in the (a–c) cortex (CTX), (d–f) dentate gyrus (DG), (g–i) cornu 
ammonis (CA), and (j–l) subiculum (SUB) in 12-month-old 5xFAD mice brain (n = 4 mice, n = 3 sections each). Panel (c, f, i, l) indicates merged 
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important that our data suggest an amyloid-associated degradation of 
white matter through the disruption of myelin lipids and therefore pro-
vides a direct connection between the extracellular amyloid plaques 
and the degeneration of myelin in white matter.
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